| Literature DB >> 34331689 |
Elahe Mohammadi1, Behzad Behnam2,3,4, Reza Mohammadinejad5, Paul C Guest6, Luis E Simental-Mendía7, Amirhossein Sahebkar8,9,10,11.
Abstract
Plant extracts have been used to treat a wide range of human diseases. Curcumin, a bioactive polyphenol derived from Curcuma longa L., exhibits therapeutic effects against diabetes while only negligible adverse effects have been observed. Antioxidant and anti-inflammatory properties of curcumin are the main and well-recognized pharmacological effects that might explain its antidiabetic effects. Additionally, curcumin may regulate novel signaling molecules and enzymes involved in the pathophysiology of diabetes, including glucagon-like peptide-1, dipeptidyl peptidase-4, glucose transporters, alpha-glycosidase, alpha-amylase, and peroxisome proliferator-activated receptor gamma (PPARγ). Recent findings from in vitro and in vivo studies on novel signaling pathways involved in the potential beneficial effects of curcumin for the treatment of diabetes are discussed in this review.Entities:
Keywords: Alpha-amylase; Alpha-glycosidase; Curcumin; Diabetes; Dipeptidyl peptidase-4; Glucagon-like peptide-1; Glucose transporter; PPARγ
Mesh：
Substances：
Year: 2021 PMID： 34331689 DOI： 10.1007/978-3-030-56153-6_9
Source DB: PubMed Journal: Adv Exp Med Biol ISSN： 0065-2598 Impact factor: 2.622